Welcome to our dedicated page for I-Mab news (Ticker: IMAB), a resource for investors and traders seeking the latest updates and insights on I-Mab stock.
I-Mab (IMAB), now NovaBridge Biosciences, reports biotechnology developments tied to precision immuno-oncology drug development for cancer. Its recurring updates center on givastomig, a Claudin 18.2 x 4-1BB bispecific antibody designed for Claudin 18.2-positive gastric cancers and other gastrointestinal tumors, and on ragistomig, a PD-L1/4-1BB bispecific antibody being developed with ABL Bio for solid tumors.
Company updates also cover clinical data presentations, trial-program activity, operating and financial results, shareholder voting matters, capital-structure disclosures, board composition, committee formation, and the completed transition from I-Mab to NovaBridge Biosciences, including the Nasdaq ADS ticker change.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.